甲苯咪唑引起肝损害

Hepatic impairment due to mebendazole

1例30岁女性患肝包虫病,术后给予口服甲苯咪唑200mg,2次/d。10d后,患者ALT升高到101U/L,将甲苯咪唑减量至100mg,2次/d。服药20d后,ALT升为200U/L,给予保肝治疗,患者肝功能降至正常范围。继续服用甲苯咪唑,患者ALT升至300U/L,再次停服甲苯咪唑。半月后患者ALT为605U/L,TBil为126μmol/L,并出现纳差、尿黄等症状。给予保肝和对症治疗,25d后患者症状好转,肝功能恢复正常。

A 30-year-old woman with hepatic echinococcosis received oral mebendazole 200 mg twice daily after operation. Ten days later, her level of ALT increased to 101 U/L. The doage of mebendazole was decreased to 100 mg twice daily. Twenty days later, her ALT increased to 200 U/L. After liver-protective treatment, the patient＇s liver function returned to normal levels. Then mebendazole was continued. The level of ALT increased to 300 U/L. Mebendazole was discontinued. Half a month later, the patient＇s ALT was 605 U/L, and TBil was 126 μmol/L. And she developed anorexia and dark yellow urine. The patient was given liver-protective and symptomatic treatment. Twenty-five days later, her symptom improved and liver function normalized.